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OBJECTIVES: This study was designed to enhance our
understanding of the burden of diabetes in the US. 
METHODS: We analyzed age-speciﬁc odds ratios, 
relative mortality rates ratios (RMRR), changes in
RMRR, prevalence, case-fatality and health care utiliza-
tion associated with combinations of 1, 2, 3, 4, and 5
concomitant diseases in diabetes, such as cardiovascular,
cerebrovascular, cancers, infectious, respiratory and
central nervous system disorders. Combinations of 
multivariate linear and logistic regression models, stan-
dard SAS procedures and original linear true basic models
were applied to a data bank system containing data in
relational and SAS formats drawn from the 1991–1996
Multiple Causes of Death Files, 1996 Medical Expendi-
ture Panel Survey, and 1987 National Medical Expendi-
ture Survey. 
RESULTS: From 1991 to 1996, the proportion of deaths
among diabetes patients <65 years grew 8.3%. The 
age group “25–29” was characterized by an estimated
61% increase in the relative mortality rate ratio of 1.5.
Respiratory conditions were associated with an estimated
23.5% of deaths among diabetes patients, compared to
23% for cerebrovascular disease. Primary causes of death
in diabetes patients increased for ischemic heart disease
(estimated 69% growth), atherosclerosis (43%), all 
respiratory conditions, including COPD (33%), breast
cancer (33%), septicemia (26%) and acute cerebrovascu-
lar disease (11%). This resulted in premature diabetic
mortality cost estimated at $3.2 billion in 1996. The 
estimated annual direct cost of treating high-risk diabetes
patients reached $36 billion, 54% of which was paid by
Medicare and Other Federal Programs. 
CONCLUSIONS: Based on the estimated increases in
case-fatality and mortality rates within employable age
groups, treatment of diabetes with concomitant cardio-
vascular, respiratory, breast cancer, cerebrovascular and
infectious diseases did not improve in the early 1990s.
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Published utility estimates can vary over a wide range
even for the same level of disease severity. As a result,
cost-utility analysts seeking secondary utilities have 
difﬁculty choosing appropriate weights for QALYs. 
OBJECTIVES: We performed two meta-analyses to
derive pooled utilities for AIDS, symptomatic HIV, and
asymptomatic HIV and minor, moderate, and major
stroke. In addition, we sought to assess the relative 
importance of study design characteristics in predicting
utility. 
METHODS: We identiﬁed 26 articles reporting 75
unique utilities for HIV/AIDS and 20 articles reporting
53 utilities for stroke. Multiple utility estimates often
appeared in the same article so that data were nested.
Consequently, we used a Hierarchical Linear Model to
perform each meta-analysis. Lacking the variance, studies
were weighted by sample size. 
RESULTS: For HIV/AIDS, disease stage (P = 0.016) and
respondents (P = 0.014) were signiﬁcant predictors of
utility while elicitation method (P < 0.1) was marginally
signiﬁcant and scale bounds were not. Pooled utility 
estimates are 0.71 for AIDS, 0.82 for symptomatic HIV,
and 0.93 for asymptomatic HIV when the time tradeoff
method is used in patients and the scale is death to perfect
health. For stroke, severity of stroke (P < 0.0001) and
scale bounds (P = 0.0015) were signiﬁcant predictors of
utility, while the elicitation method and respondents were
not. Pooled utility estimates are 0.52 for major stroke,
0.68 for moderate stroke, and 0.87 for minor stroke when
the time tradeoff method is used in community members
and the scale is death to perfect health. 
CONCLUSION: Because the pooled utility estimates
reported here are based on a comprehensive review of 
the literature, they should be of great use to researchers
performing cost-utility analyses of interventions for
HIV/AIDS as well as those designed to prevent or treat
stroke, or where stroke is a possible side effect of therapy.
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At the 2001 ISPOR Annual Meeting we presented a 
stochastic decision analysis of treatment of pyelone-
phritis with ciproﬂoxacin or trimethoprim sulphame-
thoxazole (TMP/SMX) based on an RCT. 
OBJECTIVE: Using the same dataset, the purpose of this
study is to analyze the value of funding research to reduce
the uncertainty around the decision about which drug to
prescribe. 
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METHODS: We used a non-parametric approach
employing Monte Carlo simulation to determine the
expected value of perfect information (EVPI) for the full
model and for a particular model parameter (probability
of resistance). We incorporated empiric distributions 
of the net beneﬁts associated with each treatment for
patients found to have sensitive and resistant bacteria (4
distributions for each model) created from 1,000 boot-
strap replications of the mean cost and effect. The boot-
strap replicates involved resampling from original cost
and effect data about 210 patients of whom 47 had 
bacteria resistant to TMP/SMX. In the base case the net
beneﬁts were constructed from the mean cost and effect
pairs by re-scaling the effects into a monetary value
assuming a societal willingness-to-pay $200 to prevent
one failure of treatment for pylonephritis. The model for
the population assumed an incidence of 0.4% per annum
for pyelonephritis in the US and UK and that the decision
would be valid for 10 years. 
RESULTS: Ciproﬂoxacin is the a priori choice because 
it is associated with the maximum net beneﬁt for each
diagnostic scenario for each diagnostic setting in the
model. Nonetheless, there is still residual uncertainty and
the EVPI for the decision is $2.18m for the US and £1.65
m in the UK. However, the partial evaluation revealed
that the EVPI for the prevalence of resistance is only
$3,048 in the US and £1,876 in the UK. 
CONCLUSIONS: Uncertainty about the prevalence of
resistance makes a minor contribution to the overall EVPI
for the decision.
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OBJECTIVES: The prevalence of Neisseria gonnorrhoeae
(GC) among adolescents and young women attending
urban emergency rooms (ER) ranges from 3% to 10%
but screening has historically not been feasible in this
setting. Our objective was to assess the cost-effectiveness
of newer technologies that bypass the need for a pelvic
exam and reduce loss to follow-up.
METHODS: We developed a state-transition Markov
model of the natural history of GC and simulated screen-
ing, diagnosis, and treatment in a cohort of 10,000 15-
year-old U.S. women. Adopting a societal perspective, we
compared no screening to selective age-based screening
using either the: 1) ligase chain reaction (LCR) on a urine
sample; or 2) rapid immunochromotographic assay (RIA)
on a clinician-collected vaginal sample. We assumed 80%
of LCR screen-positive women would be treated (20%
loss to follow-up) and 100% of RIA screen-positive
women would receive immediate treatment. We assumed
a peak GC prevalence of 6%. Clinical outcomes included
cases of GC, pelvic inﬂammatory disease (PID), major
PID sequelae, and quality-adjusted life expectancy
(QALE). Economic outcomes included incremental cost-
effectiveness ratios (cost per quality-adjusted life year
saved). Data were obtained from population-based
studies, national databases and published literature.
RESULTS: Compared to no screening, screening women
aged 15 to 24 with RIA was more effective and cost-
effective (i.e., dominated) than LCR and cost $1,850 per
QALY. Provided the RIA assay (base case $20) was less
than $100, the cost-effectiveness ratio for screening with
the rapid test was less than $10,000 per QALY. Results
were stable despite varying the prevalence of GC, direct
medical costs, and quality of life weights over a wide
plausible range.
CONCLUSIONS: Screening for GC within an urban-ER
setting using the new RIA test facilitates rapid screening
and treatment and has a cost-effectiveness ratio that is
more attractive than many current preventive health
interventions.
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OBJECTIVE: Brazil’s universal access to HIV treatment
and drug price reductions have affordably treated large
segments of the country’s HIV-infected population.
Several countries in Central America have large HIV-
infected populations without access to care. This analy-
sis examines the feasibility of applying Brazil’s universal
access to treatment and drug price reductions given the
economic conditions in three Central American countries:
Guatamala (n = 71,050), El Salvador (n = 19,400), and
Belize (n = 2,400). 
METHODS: Each country’s HIV population not 
currently receiving antiretroviral therapy was estimated.
For each population, the cost of two-drug and three-drug
combination antiretroviral therapy was estimated by
applying 2000 Brazilian prices (in U.S. dollars). The ratio
of drug costs to gross domestic product was determined
to measure each country’s relative ability to pay for 
the cost of treatment. The Brazilian rate of cost savings
from averted hospitalizations was subtracted from each
country’s drug cost estimates to determine total cost of
treatment. 
RESULTS: In Guatamala, the drug costs for treating the
HIV population ranges between $54.2 (0.117% of GDP)
and $335.1 (0.725%) million depending on whether
double or triple combination therapy is used. The costs
range between $14.8 (0.062%) and $91.5 (0.381%)
million in El Salvador, and between $1.8 (0.232%) and
$11.3 (1.433%) in Belize. Potential hospitalization costs
averted were $80.5 million in Guatamala, $22.0 million
in El Salvador, and $2.7 million in Belize. Given these
costs averted, the total cost of treatment ranges between
-$28.5 (cost savings) and $252.4 million in Guatamala
depending on whether double or triple combination
